Short-bowel syndrome is the most common cause of intestinal failure. Until recently, management options were limited to dietary support, anti-secretory drugs and anti-motility agents. The introduction of GLP-2 analogues have drastically changed the field, offering disease-modifying therapy which can lead to reduction of parenteral support. However, several questions remain: which is the ideal target population? When should treatment be started? Can the treatment frequency be reduced after full weaning? And how should the care for a patient treated with GLP-2 analogues be embedded in a multidisciplinary approach?
Learning Objectives
To understand the mechanism of action of GLP-2 analogues in short-bowel syndrome.
To know the expected clinical effects and adverse events during treatment with GLP-2 analogues.
To know the predictors of response to GLP-2 analogues.
To understand the multidisciplinary management of a patient treated with GLP-2 analogues.
Tim Vanuytsel Moderator
Leuven University Hospital
Belgium Bio
Prof Vanuytsel is a consultant gastro-enterologist at the University Hospitals Leuven with a clinical focus on intestinal failure, clinical nutrition and functional gastro-intestinal disorders. He is the co-founder and medical head of the Leuven Intestinal Failure and Transplant center (LIFT), which represents the largest intestinal failure and only bowel and multivisceral transplant center in Belgium. He is also assistant professor at the KU Leuven and his research interests include the pathophysiology and treatment of functional gastrointestinal disorders and intestinal failure and transplantation. He has published more than 120 original peer-reviewed papers and supervises 16 PhD students. He is the editor in chief of the Acta Gastroenterologica Belgica.
Palle Bekker Jeppesen Presenter
Department of Intestinal Failure and Liver Diseases, Rigshospitalet
Denmark Bio
Palle Bekker Jeppesen is Clinical Professor at Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; Head of Department of Intestinal Failure and Intestinal Diseases at Rigshospitalet in Copenhagen, Denmark, and he is also an Affiliate Professor in the Department of Nutrition, Exercise and Sports at the unit for Clinical and Experimental Nutrition, University of Copenhagen.
His major research interests include patients with short bowel syndrome and intestinal failure with a recent focus on novel therapies for their management, rehabilitation and care. He has been instrumental in the conduction of phase 2 and 3 trials in all GLP-2 analogs.
Professor Jeppesen graduated in medicine from the University of Copenhagen, Denmark, in 1989 and completed his residency in medical gastroenterology at the Rigshospitalet in Copenhagen. He completed his PhD thesis, entitled The significance of the fatty acid chain-length for the clinical effect in the enteral and parenteral nutrition in patients with malabsorption in 1998 and his Doctor’s Degree, entitled Intestinal insufficiency and failure, in 2003.
PBJ has published more than 150 peer-reviewed papers and book chapters within this field.
PBJ has been a member of the Scientific Committee of the European Society of Nutrition and Metabolism (ESPEN) and currently holds a position in the Intestinal Rehabilitation and Transplantation (IRTA) Council.
Francisca Joly Presenter
Beaujon Hospital – University of Paris
France Bio
Francisca Joly, MD, PhD, is a Professor of Nutrition and gastroenterologist working in Beaujon Hospital and researcher in the Gastrointestinal and Metabolic Dysfunctions in Nutritional Pathologies - Inserm UMR 1149, University of Paris. Director of Approved center of Home Parenteral Nutrition for Ile de France, Director of a constitutive centre of intestinal rare diseases in Beaujon Hospital and Medical coordinator of the Intestinal Transplantation Center for adult in Paris. Dr Joly was President of the scientific committee of SFNCM (Société francophone de nutrition Clinique et métabolisme) 2013 – 2020 and she is Member of National Council of Universities (CNU) for the nutrition field, Member of HAN-CIF group (Home Artificial Nutrition-Chronic Intestinal Failure Group) european special Interest Group of the ESPEN (European society of clinical nutrition and metabolism) since 2004 and Member of UEG scientific committee (United European Gastroenterology) since 01/2018.
Important
Disclaimer
By viewing the material on this site you understand and
accept that:
The opinions and statements expressed on this site reflect the
views of the author or authors and do not necessarily reflect those of
The Transplantation Society and/or its Sections.
The hosting of material on The Transplantation Society site does
not signify endorsement of this material by The Transplantation Society
and/or its Sections.
The material is solely for educational purposes for qualified
health care professionals.
The Transplantation Society and/or its Sections are not liable for
any decision made or action taken based on the information contained in
the material on this site.
The information cannot be used as a substitute for professional
care.
The information does not represent a standard of care.
No physician-patient relationship is being established.
International Intestinal Rehabilitation & Transplant Association
c/o The Transplantation Society
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada